Literature DB >> 22933873

Drug interactions: a primer for the gastroenterologist.

Christina Teeter Doligalski1, Angela Tong Logan, Andrew Silverman.   

Abstract

One of the most clinically significant complications related to the use of pharmacotherapy is the potential for drug-drug or drug-disease interactions. The gastrointestinal system plays a large role in the pharmacokinetic profile of most medications, and many medications utilized in gastroenterology have clinically significant drug interactions. This review will discuss the impact of alterations of intestinal pH, interactions mediated by phase I hepatic metabolism enzymes and P-glycoprotein, the impact of liver disease on drug metabolism, and interactions seen with commonly utilized gastrointestinal medications.

Entities:  

Keywords:  Drug interaction; cirrhosis; cytochrome P450 enzyme; macrolides; prokinetic agents; protease inhibitors

Year:  2012        PMID: 22933873      PMCID: PMC3424472     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  50 in total

1.  Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

Authors:  D J McConn; Y S Lin; T L Mathisen; D K Blough; Y Xu; T Hashizume; S L Taylor; K E Thummel; M C Shuhart
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

Review 2.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

3.  Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.

Authors:  N Chalasani; J C Gorski; N H Patel; S D Hall; R E Galinsky
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 4.  Summary of information on human CYP enzymes: human P450 metabolism data.

Authors:  Slobodan Rendic
Journal:  Drug Metab Rev       Date:  2002 Feb-May       Impact factor: 4.518

5.  Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

Authors:  N Buss; P Snell; J Bock; A Hsu; K Jorga
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 6.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

7.  Some pharmacological factors influencing the absorption of diazepam following oral administration.

Authors:  J A Gamble; J H Gaston; S G Nair; J W Dundee
Journal:  Br J Anaesth       Date:  1976-12       Impact factor: 9.166

8.  Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

Authors:  A D Kashuba; A N Nafziger; G L Kearns; J S Leeder; C S Shirey; R Gotschall; A Gaedigk; J S Bertino
Journal:  Pharmacogenetics       Date:  1998-10

Review 9.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 10.  Mechanisms of cytochrome P450 regulation by inflammatory mediators.

Authors:  Edward T Morgan; Tong Li-Masters; Po-Yung Cheng
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

View more
  3 in total

1.  Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers.

Authors:  Orsolya Basa-Dénes; Réka Angi; Balázs Kárpáti; Tamás Jordán; Zsolt Ötvös; Nikoletta Erdősi; Andrea Ujhelyi; Betti Ordasi; László Molnár; John McDermott; Chris Roe; Litza McKenzie; Tamás Solymosi; Gábor Heltovics; Hristos Glavinas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

2.  The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide.

Authors:  Agnieszka Karbownik; Edyta Szałek; Katarzyna Sobańska; Wojciech Połom; Tomasz Grabowski; Anna Biczysko-Murawa; Marcin Matuszewski; Anna Wolc; Edmund Grześkowiak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-28       Impact factor: 2.441

Review 3.  Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.

Authors:  Andrea Mari; Alessandro Antonelli; Luca Cindolo; Ferdinando Fusco; Andrea Minervini; Cosimo De Nunzio
Journal:  Ther Adv Urol       Date:  2021-04-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.